key: cord-0885287-5ox7km1n
authors: Partinen, Markku
title: Sleep research in 2020: COVID-19-related sleep disorders
date: 2020-12-16
journal: Lancet Neurol
DOI: 10.1016/s1474-4422(20)30456-7
sha: c333c973b17b89feca0a8b10ee5d130283f9d35d
doc_id: 885287
cord_uid: 5ox7km1n

nan

Repurposed drugs for ALS are also of increasing interest, as evidenced by promising results from a phase 2 doubleblind placebo-controlled study of AMX0035. 10 This combination of sodium phenylbutyrate and taurur sodiol was designed to prevent neuronal death by simultaneously mitigating endoplasmic reticulum stress and mitochondrial dysfunction. The mean rate of decline in ALSFRS-R total score was significantly slower with AMX0035 than with placebo. A separate phase 3 study of taurusodiol versus placebo is underway in Europe, and it is likely that an additional phase 3 trial of AMX0035 will be initiated in 2021.

Finally, the impact of the COVID-19 pandemic on clinical research in ALS has been considerable. There has been a significant shift to remote monitoring using telemedicine, as reflected in numerous publications over the past 6 months. COVID-19 has also necessitated a paradigm shift for the future design and execution of clinical trials, with a change in emphasis from in-clinic evaluation to home monitoring. Home monitoring opens opportunities for repeated testing of defined outcomes over shorter periods, providing a richer dataset of outcome measures that could, in future, reduce variance and improve reliability.

OH is the editor-in-chief of the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, and has consulted for Cytokinetic, Wave Life Sciences, Novartis, Orion, and Denali. 

2020 has been an unprecedented year because a modified coronavirus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), spread rapidly from China to all continents, leading to the COVID-19 pandemic.

The first studies of COVID-19-associated sleep dis orders were reported in China. Huang and Zhao 1 collected information from a survey of 7236 volunteers (mean age 35·3 years [SD 5·6]). About a third of them were healthcare workers. About 35% of these participants reported symptoms of general anxiety, 20% of depression, and 18% of poor sleep quality. 1 The participants who were most worried about the pandemic also reported the most symptoms. Health-care workers were clearly under great pressure, which was reflected in the high prevalence of mental-health symptoms that they reported. 1 The increased prevalence of sleep dis orders in 2020 has also been highlighted in several other publica tions from different countries. These studies examined the effect on sleep of SARS-CoV-2 infection and confounders related to isolation, quarantine, anxiety, stress, or financial losses. According to a European task force, symptoms of insom nia could be related to psychosocial factors and to the confinements. 2 In Italy, anxiety related to COVID-19 was highly associated with disturbed sleep. In a survey of 2291 Italians, 57·1% reported poor sleep quality, 32·1% high anxiety, 41·8% high distress, and 7·6% reported post-traumatic symptoms of stress. 3 In the International COVID-19 Sleep Study, 4 different factors are being investigated using a harmonised set of questions. Insomnia, nightmares, sleep apnoea, fatigue, exhaustion, and REM sleep behaviour disorder are being investigated by this collaboration. 4 The hypothesis is that fatigue, sleepiness, and REM sleep behaviour disorder might be related to SARS-CoV-2 infection per se, whereas insomnia might be related mainly to confinement, anxiety, and other psychosocial factors. 2 Although studies related to COVID-19 have dominated the field in 2020, other important investigations have also been published. Untreated severe sleep apnoea is associated with poor health and cardiovascular mor bidity and mortality. However, the cost-effectiveness of treating mild severe sleep apnoea with continuous positive airway pressure (CPAP) is still unclear. Two important randomised studies on the treatment of patients with severe sleep apnoea have been reported. The MERGE trial in the UK, which included 233 participants with mild untreated severe sleep apnoea (defined as having scores of 5-14 on the Apnoea-Hypopnoea Index [AHI]), showed that CPAP significantly improved quality of life (as measured by the Short Form Health Survey). 5 Although this study is methodologically robust, it does not provide final answers, and its follow-up time was short (only 3 months). Although 81% of the treated participants were willing to continue CPAP after completion of the trial, the improved quality of life might have been due to other factors. Effects of body-mass index, physical exercise, and sleepiness on quality of life were not analysed. All patients with untreated severe sleep apnoea should lose weight if they are obese, avoid excessive stress, and have a healthy lifestyle. CPAP can therefore not be routinely recommended for all cases of mild untreated severe sleep apnoea. In addition to their subjective quality of life, assessing daytime functioning in these patients is crucial.

Another large randomised study was done in Spain. The ISAAC study recruited 2551 individuals. 6 Of the 1264 patients without excessive daytime sleepi ness (Epworth Sleepiness Scale score [ESS] ≤10) and moderateto-severe untreated sleep apnoea (AHI scores ≥15), 633 were randomly assigned to receive CPAP and 631 to receive usual care. The median follow-up time was 3·35 years. No significant differences in the occurrence of cardiovascular events were found. 98 (16%) of the events were observed in the CPAP group and 108 (17%) in the usual care group. The hazard ratio was 0·89 (95% CI 0·68-1·17; p=0·40). 6 Further important findings in sleep medicine came from Hablitz and colleagues, 7 who showed that CSF distribution is under circadian control. Researchers in Copenhagen (Denmark) and Rochester (New York, USA) have proposed that interstitial ion signalling is crucial in controlling sleep and wakefulness. 8 These investigators have also proposed that ion homoeostasis failure might contribute to neurological diseases and cognitive-behavioural disorders. 8 New studies done by Erlend Nagelhus and colleagues also show that Ca2+ signalling is essential in the regulation of slow wave sleep. 9 All of these new studies support that astrocytes are key elements in the regulation of brain function. Emerging evidence indicates that disturbed sleep might be among the strongest risk factors for development of neurodegenerative diseases. Therefore, all physi cians should incorporate questions about sleep hygiene and quality into their routine clinical practice.

Although there have been many contributions to advance our understanding of neurological infections in 2020, the year has been dominated by research focused on the neurological consequences of COVID-19. Multidisciplinary studies are ongoing to better differen tiate the direct effects of severe acute respiratory syn drome coronavirus 2 (SARS-CoV-2) versus its secon dary effects (PMC7184392, NCT04386083, and CTRI/2020/07/026339). Nevertheless, it has become clear that there is a striking incidence of neurological involvement in this disease, the symptoms of which span reversible anosmia, stroke-related disability, and death. [1] [2] [3] Dry cough, fever, dyspnoea, nausea, emesis, and fatigue are common symptoms of SARS-CoV-2 infection 1 -a profile shared with numerous viral infections. However, anosmia and ageusia, which have now been documented in ample research, 1,2,4 are symptoms more distinctive of SARS-CoV-2 infection than other common viral infections, and the implications of these symptoms drive our understanding of the unique pathophysiology of COVID-19. In one of the largest studies to date, 3191 individuals infected with SARS-CoV-2 were surveyed to assess the prevalence of anosmia and ageusia. 488 (15·3%) individuals were found to have one or both of these symptoms; in most cases, taste and smell were fully recovered 7 days after onset on average. 1 Smaller studies have shown anosmia to be much more prevalent and the heralding symptom of SARS-CoV-2 infection, 5 therein identifying a potential source of viral replication and CNS invasion.

Subsequently, hypotheses emerged regard ing the poten tial for viral neurotropism and a direct route of entry into the CNS from the olfactory bulbs. In an imaging study 6 of 23 patients with confirmed SARS-CoV-2 infection with clinical anosmia, SARS-CoV-2-related olfactory dys func tion was differentiated from other viral olfactory dysfunction in several crucial ways. Postviral anosmia in the setting of upper respiratory tract infections is usually related to mucosal congestion and nasal obstruction, resulting in a conductive olfactory loss; however, few patients with SARS-CoV-2-related anosmia had sinonasal symptoms, suggesting that mucosal congestion is an unlikely aetiology for anosmia in these cases. 6 Olfactory epithelium support-cells residing in the olfactory cleft express the angiotensin-converting enzyme 2 receptor, identified as the binding antigen for SARS-CoV-2. 6 Imaging of the olfactory cleft showed olfactory cleft opacification in 17 (74%) of cases. 6 Moving proxi mally, olfactory nerve filia clumping, sug gestive of inflammation, was observed in eight (35%) of patients, and olfactory bulb signal abnormalities, indicating degenera tion or micro haemorrhage, were seen in 21 (91%) individuals. Within the CNS, hyperintense T2 or fluidattenuated inversion recovery signals in the olfactory cortex were found in five (22%) individuals.

An association has been shown between SARS-CoV-2 infection and acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 7 extending the viral pathogenic effects to the peripheral nervous system. In a case series of five individuals with AIDP and SARS-CoV-2 infection, the latency between res pira tory symptom and neurological symptom onset was 14-30 days. 7 Most patients presented with the classical findings of AIDP, with ascending paraparesis and hyporeflexia, conduction blocks and increased latency on nerve con duction studies, and albuminocytological dissociation in the

Dealing with sleep problems during home confinement due to the COVID-19 outbreak: practical recommendations from a task force of the European CBT-I Academy

The enemy who sealed the world: effects quarantine due to the COVID-19 on sleep quality, anxiety, and psychological distress in the Italian population

Sleep and circadian problems during the coronavirus disease 2019 (COVID-19) pandemic: the International COVID-19 Sleep Study (ICOSS)

Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial

Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial

Circadian control of brain glymphatic and lymphatic fluid flow

Interstitial ions: a key regulator of state-dependent neural activity?

Astrocytic Ca 2+ signaling is reduced during sleep and is involved in the regulation of slow wave sleep